dromlakhani Perform digital rectal examination before testosterone therapy
STEP 1 — Gather Information
Collect symptoms of hypogonadism (low libido, decreased morning erections, fatigue), confirm total testosterone <12 nmol/L on two separate morning fasting samples, and assess for contraindications to testosterone therapy.
Action: If symptomatic and biochemically confirmed hypogonadism, proceed to evaluate need for DRE; otherwise, do not initiate testosterone therapy.
STEP 2 — Rule In / Rule Out
Is the patient a candidate for testosterone therapy (symptomatic with confirmed low T)?
- Yes: Proceed to DRE.
- No: Do not start testosterone therapy; DRE not required.
Decision: Based on the binary fork, either advance to DRE or withhold testosterone therapy.
STEP 3 — Classify or Stratify
After DRE, classify prostate findings: normal size, reduced size (suggestive of hypogonadism), enlarged benign (smooth, symmetrical), or suspicious (nodularity, hardness, asymmetry).
Action: If normal or reduced size, consider testosterone therapy; if enlarged benign, discuss risks and may proceed with monitoring; if suspicious, defer testosterone therapy and refer for urologic evaluation (PSA, biopsy).
STEP 4 — Decide
Based on DRE classification, decide to initiate testosterone therapy after shared decision‑making if the exam is non‑suspicious; otherwise, obtain PSA and refer to urology before considering testosterone therapy.
Decision: Start testosterone therapy with baseline PSA and plan for repeat DRE per monitoring schedule, or obtain further urologic work‑up if DRE is abnormal.
Clinical Guardrails / Mimics / Pitfalls
DRE does not exclude prostate cancer; PSA should be obtained per guidelines. Do not start testosterone therapy if DRE shows a suspicious nodule without further evaluation. DRE may miss anterior zone cancers. Ensure informed consent discussing benefits, risks, and monitoring requirements. Consider anticoagulation status before performing DRE.
Concrete Clinical Example
A 58‑year‑old man reports decreased libido and fatigue; total testosterone is 10 nmol/L on two occasions. Clinician performs DRE, finds a symmetrically enlarged prostate without nodules. After discussing risks and benefits, testosterone therapy is initiated with a baseline PSA and a plan for repeat DRE at 6 months.
Source: Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, DOI: 10.1093/sxmrev/qeaf036